APIM Therapeutics Closes a Financing Round

TRONDHEIM, Norway, October 17, 2012 /PRNewswire/ --

- Financing will be used to further develop APIM Therapeutics lead anti-cancer compound towards late preclinical development.

APIM Therapeutics, a preclinical biotech company focusing on the development of novel peptide therapeutics targeting PCNA (Proliferating Cell Nuclear Antigen), a validated cancer target implicated in the regulation of cellular responses to various stress signals, announces the closure of a financing round enabling the company to further advance its lead compound, ATX-101, towards IND-enabling regulatory studies. To date, ATX-101 has shown promising activity in several preclinical solid tumor and blood cancer models and is capable of potentiating the action of >15 clinical drugs.

     (Logo: http://photos.prnewswire.com/prnh/20121017/567974 )

The investment is led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed (Bergen, Norway), Birk Venture and Ro Invest (Oslo, Norway).

APIM Therapeutics was established in 2009 as a result of several years of scientific work at Prof. M. Otterlei's laboratory at the Norwegian University of Science and Technology (NTNU). This research has identified a novel therapeutic intervention point relevant for the treatment of a large variety of cancer cells including, among others, bladder cancer and multiple myeloma.

Konstantinos Alevizopoulos, CEO of APIM Therapeutics: "We are delighted to have secured this additional funding in APIM Therapeutics which will allow for further preclinical development of our novel therapeutic concept".

Jørgen André Nilsen, a Partner in Norsk Innovasjonskapital III: "We are pleased to support the advancement of APIM's novel anti-cancer treatment. We believe that the company offers a unique therapeutic approach that may provide novel therapeutic options to cancer patients.

http://www.apimtherapeutics.com

Additional Web Sites
Norsk Innovasjonskapital III (http://www.televenture.no)
Sarsia Seed (http://www.sarsiaseed.com)
Birk Ventures (http://www.birkventure.no)              
NTNU (http://www.ntnu.no)


E-mail: [email protected]

SOURCE APIM Therapeutics

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.